Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Biosergen AB: BioStock: Biosergen discusses positive results in patients with deadly fungal infections

Biosergen

So far, the majority of patients involved in Biosergen's proof-of-concept study for life-threatening fungal infections have been able to leave the hospital. This suggests the potential effect of BSG005 even at low doses. Moreover, the subscription period for the company's TO3 warrants is approaching, which will take place between November 18 and 29.

Watch the interview with CEO Tine Olesen at biostock.se:

https://www.biostock.se/en/2024/11/biosergen-discusses-positive-results-in-patients-with-deadly-fungal-infections/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.